INSERM, Center of Clinical Investigation 9501, Institut Lorrain du Coeur et des Vaisseaux, CHU Nancy, Université de Lorraine, Nancy, France.
Eur J Heart Fail. 2014 Jan;16(1):76-85. doi: 10.1093/eurjhf/hft129. Epub 2013 Dec 3.
Heart rate not only predicts outcome but may also be a therapeutic target in patients with chronic heart failure. Several classes of pharmacological agents can be used to modulate heart rate, including beta-blockers, ivabradine, digoxin, amiodarone, and verapamil. Choice of agent will depend on heart rhythm, co-morbidities, and disease phenotype. Beneficial and harmful interactions may also exist. The aim of this paper is to summarize the current body of knowledge regarding the relevance of heart rate as a prognostic factor (risk marker) and particularly as a therapeutic target (risk factor) in patients with chronic heart failure, with a special focus on ivabradine, a novel agent that is currently the only available purely bradycardic agent.
心率不仅可以预测结局,而且可能成为慢性心力衰竭患者的治疗靶点。有几类药物可以用来调节心率,包括β受体阻滞剂、伊伐布雷定、地高辛、胺碘酮和维拉帕米。药物的选择取决于心律、合并症和疾病表型。有益和有害的相互作用也可能存在。本文的目的是总结目前关于心率作为慢性心力衰竭患者预后因素(风险标志物)和治疗靶点(风险因素)的相关知识,特别关注伊伐布雷定,这是一种新型药物,也是目前唯一可用的纯缓慢性药物。